Effect of oral @entity1140 ( @entity1140 ) on @entity134 -refractory moderate/severe XXXX .

@entity1 @entity500 @entity882 @entity548 @entity31 @entity205 @entity134 @entity1140
BACKGROUND: @entity134 refractory @entity31 is most commonly treated with intravenous @entity205 to avoid colectomy. In search for an alternative drug that can be administered orally we investigated oral @entity1140 ( @entity1140 ) for this indication. METHODS: Nine @entity1 with active, moderate/severe @entity134 refractory UC were treated with oral @entity1140 with a daily dose of 0.15 mg/kg body weight. After @entity1 had responded @entity500 was added for long-term immunosuppression. RESULTS: All @entity1 responded within 1-2 weeks. After 12 weeks of @entity1140 therapy six @entity1 (67%) were in complete remission, two @entity1 (22%) had mild to moderate disease activity, and one @entity1 (11%) underwent colectomy. After a mean follow up of 21 months six of the nine @entity1 (67%) had their colon in situ. Two @entity1 developed severe side-effects, one @entity882 with @entity548 , and one bicytopenia. Mild side-effects were common. CONCLUSION: Oral @entity1140 may be an effective alternative to intravenous @entity205 for the therapy of @entity134 -refractory @entity31 . @entity1 receiving @entity1140 need to be watched carefully for side-effects.
